Zobrazeno 1 - 10
of 165
pro vyhledávání: '"Chien‐Yu Cheng"'
Autor:
Ju‐Yu Wu, Yi‐Chun Lin, Shu‐Yuan Lee, Cheng‐Pin Chen, Shu‐Hsing Cheng, Chien‐Yu Cheng, Congo Tak Shing Ching, Hui‐Min David Wang, Chu‐Chun Yeh, Wei J. Chen, Wei‐Wen Chen, Lun‐De Liao
Publikováno v:
Global Challenges, Vol 8, Iss 12, Pp n/a-n/a (2024)
Abstract Healthcare‐associated infection (HAI) is the most common adverse medical event that affects patients. Internationally, healthcare workers (HCWs) are monitored for hand hygiene compliance to reduce HAI risk. While direct observation is cons
Externí odkaz:
https://doaj.org/article/f4061dd8ad084a26a0351b6766909639
Autor:
Chien-Yu Cheng, Ying-Shih Su, Chyi-Liang Chen, Mingi Chang, Shu-Wei Huang, Peng-Nien Huang, Shin-Ru Shih, Yu-Shen Hsu, Cheng-Hsun Chiu
Publikováno v:
Human Vaccines & Immunotherapeutics, Vol 20, Iss 1 (2024)
The objective of the study was to assess the safety, tolerability, and potential efficacy of intranasally administered AD17002, a detoxified form of Escherichia coli heat-labile enterotoxin, in treating individuals with mild-to-moderate coronavirus d
Externí odkaz:
https://doaj.org/article/535741db233447fcaa13edccaefc2375
Autor:
Wang-Da Liu, Po-Hao Feng, Chien-Yu Cheng, Chun-Liang Chou, Chih-Hsin Lee, Min-Chi Lu, Po-Yu Liu, Mei-Hui Lee, Chun-Hsing Liao, Mei-Chuan Chen, Cheng-Pin Chen, Shang-Fu Hsu, Yu-Tien Tzeng, Yi-Chun Lin, Tsong-Yih Ou, Albert Qin, Chan-Yen Tsai, Weichung Joe Shih, Kang-Yun Lee, Wang-Huei Sheng
Publikováno v:
Infectious Diseases and Therapy, Vol 13, Iss 7, Pp 1575-1588 (2024)
Abstract Introduction Ropeginterferon alfa-2b is a novel mono-pegylated proline-interferon. This clinical study aimed to evaluate its antiviral efficacy of ropeginterferon alfa-2b against SARS-CoV-2 infection. Methods This is a multicenter, randomize
Externí odkaz:
https://doaj.org/article/c4d086975f614f53bd26100305caa75e
Autor:
Chun-Chi Yang, Chung-Feng Huang, Te-Sheng Chang, Ching-Chu Lo, Chao-Hung Hung, Chien-Wei Huang, Lee-Won Chong, Pin-Nan Cheng, Ming-Lun Yeh, Cheng-Yuan Peng, Chien-Yu Cheng, Jee-Fu Huang, Ming-Jong Bair, Chih-Lang Lin, Chi-Chieh Yang, Szu-Jen Wang, Tsai-Yuan Hsieh, Tzong-Hsi Lee, Pei-Lun Lee, Wen-Chih Wu, Chih-Lin Lin, Wei-Wen Su, Sheng-Shun Yang, Chia-Chi Wang, Jui-Ting Hu, Lein-Ray Mo, Chun-Ting Chen, Yi-Hsiang Huang, Chun-Chao Chang, Chia-Sheng Huang, Guei-Ying Chen, Chien-Neng Kao, Chi-Ming Tai, Chun-Jen Liu, Mei-Hsuan Lee, Hsing-Tao Kuo, Pei-Chien Tsai, Chia-Yen Dai, Jia-Horng Kao, Han-Chieh Lin, Wang-Long Chuang, Kuo-Chih Tseng, Chi-Yi Chen, Ming-Lung Yu
Publikováno v:
Infectious Diseases and Therapy, Vol 13, Iss 6, Pp 1199-1213 (2024)
Abstract Introduction Eight-week glecaprevir/pibrentasvir (GLE/PIB) is indicated for treatment-naïve (TN) patients with chronic hepatitis C (CHC), with or without compensated cirrhosis. Given that the Taiwanese government is committed to eliminating
Externí odkaz:
https://doaj.org/article/14215fa1ee784d7ab2393d1356d5db36
Autor:
Ming-Ying Lu, Chung-Feng Huang, Chao-Hung Hung, Chi‐Ming Tai, Lein-Ray Mo, Hsing-Tao Kuo, Kuo-Chih Tseng, Ching-Chu Lo, Ming-Jong Bair, Szu-Jen Wang, Jee-Fu Huang, Ming-Lun Yeh, Chun-Ting Chen, Ming-Chang Tsai, Chien-Wei Huang, Pei-Lun Lee, Tzeng-Hue Yang, Yi-Hsiang Huang, Lee-Won Chong, Chien-Lin Chen, Chi-Chieh Yang, Sheng‐Shun Yang, Pin-Nan Cheng, Tsai-Yuan Hsieh, Jui-Ting Hu, Wen-Chih Wu, Chien-Yu Cheng, Guei-Ying Chen, Guo-Xiong Zhou, Wei-Lun Tsai, Chien-Neng Kao, Chih-Lang Lin, Chia-Chi Wang, Ta-Ya Lin, Chih‐Lin Lin, Wei-Wen Su, Tzong-Hsi Lee, Te-Sheng Chang, Chun-Jen Liu, Chia-Yen Dai, Jia-Horng Kao, Han-Chieh Lin, Wan-Long Chuang, Cheng-Yuan Peng, Chun-Wei- Tsai, Chi-Yi Chen, Ming-Lung Yu
Publikováno v:
Clinical and Molecular Hepatology, Vol 30, Iss 1, Pp 64-79 (2024)
Background/Aims Despite the high efficacy of direct-acting antivirals (DAAs), approximately 1–3% of hepatitis C virus (HCV) patients fail to achieve a sustained virological response. We conducted a nationwide study to investigate risk factors assoc
Externí odkaz:
https://doaj.org/article/29b467adfe714190932d96e188f51734
Autor:
Matthew G. Johnson, Julie M. Strizki, Erin Jensen, Jonathan Cohen, Christine Katlama, Roman Fishchuk, Alfredo Ponce-de-León, Nyda Fourie, Chien-Yu Cheng, Dorothy McCoy, Mary Vesnesky, Carmelle T. Norice, Ying Zhang, Angela Williams-Diaz, Michelle L. Brown, Patricia Carmelitano, Jay A. Grobler, Amanda Paschke, Carisa De Anda
Publikováno v:
Microbiology Spectrum, Vol 12, Iss 3 (2024)
ABSTRACTThis exploratory post hoc analysis assessed the incidence of respiratory viral coinfections and their impact on clinical outcomes in non-hospitalized adults with mild-to-moderate coronavirus disease-2019 (COVID-19) treated with molnupiravir v
Externí odkaz:
https://doaj.org/article/932e80f2671449e2b10135227fadd4ab
Autor:
Yen-Fang Huang, Fang-Chi Hsu, Jiunn-Jong Wu, Yi-Ling Lin, Ming-Tsan Liu, Chin-Hui Yang, Hsu-Sung Kuo, Yen-Ju Chen, Chien-Yu Cheng, His-Hsun Lin, Chun-Che Liao, Chih-Shin Chang, Jian-Jong Liang, Wen-Yueh Cheng, Jason C. Huang, Cheng-Pin Chen, Shu-Hsing Cheng, Yi-Chun Lin, Shung-Haur Yang, Yiing-Jenq Chou
Publikováno v:
Journal of Microbiology, Immunology and Infection, Vol 56, Iss 3, Pp 506-515 (2023)
Background: Understanding the neutralizing antibody (NAb) titer against COVID-19 over time is important to provide information for vaccine implementation. The longitudinal NAb titer over one year after SARS-CoV-2 infection is still unclear. The purpo
Externí odkaz:
https://doaj.org/article/6d9a76cc23de4298b8e8496e61cc651a
Autor:
Aristine Cheng, Ming-Ju Hsieh, Sui-Yuan Chang, Si-Man Ieong, Chien-Yu Cheng, Wang-Huei Sheng, Shan-Chwen Chang
Publikováno v:
Journal of the Formosan Medical Association, Vol 122, Iss 5, Pp 384-392 (2023)
Background: Studies correlating reactogenicity and immunogenicity of COVID-19 vaccines are limited to BNT162b2, with inconsistent results. We investigated whether adverse reactions after other COVID-19 vaccines reliably predict humoral responses. Met
Externí odkaz:
https://doaj.org/article/2c6cd06c0e284f97ac58c687fa863d95
Autor:
Cathrine Axfors, Andreas M. Schmitt, Perrine Janiaud, Janneke van’t Hooft, Sherief Abd-Elsalam, Ehab F. Abdo, Benjamin S. Abella, Javed Akram, Ravi K. Amaravadi, Derek C. Angus, Yaseen M. Arabi, Shehnoor Azhar, Lindsey R. Baden, Arthur W. Baker, Leila Belkhir, Thomas Benfield, Marvin A. H. Berrevoets, Cheng-Pin Chen, Tsung-Chia Chen, Shu-Hsing Cheng, Chien-Yu Cheng, Wei-Sheng Chung, Yehuda Z. Cohen, Lisa N. Cowan, Olav Dalgard, Fernando F. de Almeida e Val, Marcus V. G. de Lacerda, Gisely C. de Melo, Lennie Derde, Vincent Dubee, Anissa Elfakir, Anthony C. Gordon, Carmen M. Hernandez-Cardenas, Thomas Hills, Andy I. M. Hoepelman, Yi-Wen Huang, Bruno Igau, Ronghua Jin, Felipe Jurado-Camacho, Khalid S. Khan, Peter G. Kremsner, Benno Kreuels, Cheng-Yu Kuo, Thuy Le, Yi-Chun Lin, Wu-Pu Lin, Tse-Hung Lin, Magnus Nakrem Lyngbakken, Colin McArthur, Bryan J. McVerry, Patricia Meza-Meneses, Wuelton M. Monteiro, Susan C. Morpeth, Ahmad Mourad, Mark J. Mulligan, Srinivas Murthy, Susanna Naggie, Shanti Narayanasamy, Alistair Nichol, Lewis A. Novack, Sean M. O’Brien, Nwora Lance Okeke, Léna Perez, Rogelio Perez-Padilla, Laurent Perrin, Arantxa Remigio-Luna, Norma E. Rivera-Martinez, Frank W. Rockhold, Sebastian Rodriguez-Llamazares, Robert Rolfe, Rossana Rosa, Helge Røsjø, Vanderson S. Sampaio, Todd B. Seto, Muhammad Shahzad, Shaimaa Soliman, Jason E. Stout, Ireri Thirion-Romero, Andrea B. Troxel, Ting-Yu Tseng, Nicholas A. Turner, Robert J. Ulrich, Stephen R. Walsh, Steve A. Webb, Jesper M. Weehuizen, Maria Velinova, Hon-Lai Wong, Rebekah Wrenn, Fernando G. Zampieri, Wu Zhong, David Moher, Steven N. Goodman, John P. A. Ioannidis, Lars G. Hemkens
Publikováno v:
Nature Communications, Vol 15, Iss 1, Pp 1-2 (2024)
Externí odkaz:
https://doaj.org/article/eaaad84f79e74e2bbfb5c0c8a4146fc5
Autor:
Shu-Yuan Lee, Yi-Chun Lin, Cheng-Pin Chen, Shu-Hsing Cheng, Shu-Ying Chang, Shin-Yen Ku, Chien-Yu Cheng
Publikováno v:
PLoS ONE, Vol 19, Iss 11, p e0314003 (2024)
Conflicting data exists regarding the baseline determinants of virological nonsuppression outcomes in treatment-experienced people living with human immunodeficiency virus (PWH) switching to antiretroviral treatment (ART) with bictegravir/emtricitabi
Externí odkaz:
https://doaj.org/article/0ba5b4f605ce4713a1e65154333d04df